10x Science raises $4.8M to help drug makers sort through AI-generated molecules and pick winners

10x Science closed a $4.8 million seed funding round to build software that helps pharmaceutical researchers evaluate molecules discovered by AI. AI tools can now generate thousands of candidate drug compounds in days, but researchers lack a fast way to decide which ones are worth testing in the lab — creating a bottleneck that slows drug development.

The startup's platform helps chemists understand the properties and behavior of complex molecules (3D structures made of atoms bonded together) without needing to run expensive lab experiments first. Instead of testing 500 candidates physically, researchers can filter down to 50 promising ones computationally, saving months and millions in lab costs.

For pharmaceutical companies and biotech startups, this means faster drug discovery pipelines and lower R&D costs — making it feasible to pursue rare diseases or smaller-market therapies that weren't economically viable before. For patients, it could shorten the gap between AI-designed drugs and medicines that actually reach the clinic.